NCT04505189 is a Phase 1, PHASE2 clinical trial of Psilocybin in Anorexia Nervosa, sponsored by Imperial College London.

Who is sponsoring NCT04505189?

NCT04505189 is sponsored by Imperial College London.

What drugs are being tested in NCT04505189?

Interventions in NCT04505189: Psilocybin.

What condition does NCT04505189 study?

NCT04505189 studies Anorexia Nervosa.

Is NCT04505189 still recruiting?

NCT04505189 is currently completed. Last updated 17 June 2024.

Last reviewed 2024-06-17 · How we verify

NCT04505189

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study

Completed Phase 1, PHASE2 Last updated 17 June 2024

What this trial tests

Phase 1, PHASE2 trial testing Psilocybin in Anorexia Nervosa in 21 participants. Completed in 12 June 2024.

Timeline

28 May 2021

Primary endpoint
11 December 2023

12 June 2024

Quick facts

Lead sponsor	Imperial College London
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	28 May 2021
Primary completion	11 December 2023
Estimated completion	12 June 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

Psilocybin — full drug profile →

Conditions studied

Anorexia Nervosa — all drugs for Anorexia Nervosa →

Sponsor

Imperial College London

Who can join

Adults 21 to 65, female only, with Anorexia Nervosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to assess the acceptability and efficacy of treating anorexia nervosa with psilocybin. The secondary aim of this study is to use Magnetic Resonance Imaging (MRI) and Electroencephalography (EEG) to examine the neuronal underpinnings of treatment with psilocybin in this patient group.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.
Peck SK, Shao S, Gruen T, Yang K, et al · · 2023 · cited 80× · PMID 37488291 · DOI 10.1038/s41591-023-02455-9
Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study".
Spriggs MJ, Douglass HM, Park RJ, Read T, et al · · 2021 · cited 47× · PMID 34744825 · DOI 10.3389/fpsyt.2021.735523
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice.
Fadahunsi N, Lund J, Breum AW, Mathiesen CV, et al · · 2022 · cited 41× · PMID 35953488 · DOI 10.1038/s41398-022-02103-9
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.
Kelly JR, Gillan CM, Prenderville J, Kelly C, et al · · 2021 · cited 36× · PMID 34975593 · DOI 10.3389/fpsyt.2021.800072
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Mitchell JM, Anderson BT. · · 2024 · cited 32× · PMID 37479859 · DOI 10.1038/s41386-023-01656-7
Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms.
Conn K, Milton LK, Huang K, Munguba H, et al · · 2024 · cited 27× · PMID 38678087 · DOI 10.1038/s41380-024-02575-9
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions.
Ragnhildstveit A, Slayton M, Jackson LK, Brendle M, et al · · 2022 · cited 27× · PMID 35326338 · DOI 10.3390/brainsci12030382
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
Mastinu A, Anyanwu M, Carone M, Abate G, et al · · 2023 · cited 17× · PMID 36674849 · DOI 10.3390/ijms24021329

Verify or expand the search:

Other trials of Psilocybin

Trials testing the same drug.

NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting
NCT07226232 — Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression · Phase 3 · not yet recruiting
NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT07506395 — Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder · Phase 1 · not yet recruiting

Other recruiting trials for Anorexia Nervosa

Currently open trials in the same condition.

NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
NCT07188155 — Adapting Exposure for Adolescent AN · NA · recruiting
NCT07143981 — The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa · recruiting
NCT07311356 — Prognosis of Early-onset Anorexia Nervosa · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04505189 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 17 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04505189.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing